Lymphoma. Hodgkinlymfomen and non-Hodgkin's disease
Information on current developments in both regular and alternative or complementary treatments and resources for lymphoma - non-Hodgkin's lymphoma and Hodgkin's disease at all stages.
Recent articles in left column more or less in alphabetical order classified
Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.
BiovaxID immunotherapy: a vaccination with significantly longer disease-free time at lymfklier gives cancer (non-Hodgkin-FL) seen from phase III study. Article update 11 January 2011
This article is a few hours worked. Lookup, translate, places etc. If you want to support us you can do so through a donation anonymous or not. Any amount is welcome no matter how small. Click here if you want to help us to keep cancer-news online We are an ANBI organization and so your donation is tax-deductible.
11 January 2012:
Interesting to mention is in addition to the information below a summary article of the approach with radio therapy-irradiation in combination with shapes of chemo and immuuntherapeutische resources including Zevalin and Bexxar and Yttrium-90: Radioimmunotherapy or Non-Disease Lymphoma: From the ' Magic Bullets ' to ' Radioactive Magic Bullets '
In the abstract state this, but click on this link for the full study report.
Down state information about immunotherapies with BiovaxID ®. If you click here you can read and see how you as a patient may obtain BiovaxID ® can:
Source: Radioimmunotherapy (RIT) or lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory follicular CD20 + B-cell non-Hodgkin's lymphoma ´ s. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Disease lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation or ride. The predominant hematological toxicity complication or ride is that is usually manageable. There are ongoing trials to further define the expanding role of RIDE as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role or RIDE in treatment of non-Disease lymphoma, which is established or clinical utility and FDA approved. The mechanism of RIDE, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.
17 January 2010: source: Abramson Cancer Center of the University of Pennsylvania
A vaccine called BiovaxID that is made of the tumor tissue of the patient gives itself significantly longer disease-free time at cancer-non-Hodgkin's lymfklier of the type Follicular Lymphoma (FL) in patients who already 6 months disease-free time with chemo had reached.
117 participants were given the vaccine along with a immuunstimulator GM-csf (76 participants) or placebo (41 participants).They all had stage II to IV and had at least with help of reached 6 months remission chemotherapy (PACE regime). The study is still running but in an intermediate evaluation these results are released there. The median follow-up time at this between evaluation was 56.6 months.The median time to recurrence was 44.2 months for the vaccine against group 30.6 months before the placebgroep. This is statistically significant (p = 0,045). The overall survival has not yet been reached with more than 95% of the vaccine group and 91% of the placebo group still life at the time of this evaluation.No serious side effects were attributed to the vaccine and the adverse reactions were similar in both groups had 234 participants registered initially. but it fell 25% because they have not reached the 6 months disease-free time. The researchers argue now for studies with Rituxan and without chemo or advance to chemo. A nice result at aimmunotherapies similar to dendritic cell therapy if fresh tumor tissue for hands.
Original abstract:
Title: follicular lymphoma Idiotype vaccine therapy (BiovaxID) in first complete remission: in Phase III clinical trial results
Presenter: S. J. Schuster, MD
Affiliation: University of Pennsylvania
Non-Disease Lymphoma (NHL) is the 6th most common type of cancer in the US. There will be approximately 65,980 news cases diagnosed in the US in 2009.
Follicular Lymphoma (FL) is the 2nd most common type of NHL and accounts for 25% of all NHL. It is a B-cell derived neoplasm, which expresses a specific idiotype marker on the surface of tumor cells. Despite effective chemotherapy regi man, this type of lymphoma typically recurs and becomes resistant to therapy. This study evaluated the use of a vaccine created from the patient's tumor cells.
Participants had been in remission for at least 6 months after standard chemotherapy (though not Rituxan, as this was not yet standard when the study started). A "personalized" vaccine was made for each patient using tissue from lymph node biopsies. Unique markers were identified for each person's lymphoma and, from this, a vaccine that targets this marker was created. The vaccine was then given in conjunction with an immune stimulating agent called GM-CSF, which helps to stimulate an immune response. Normal cells are spared any damage because they do not have the target marker.
One-hundred and seventeen participants received either vaccine (76 patients) or placebo (41 pts). They had stage IIx-IV FL and had achieved at least a 6 month remission after chemotherapy (regimen used was PACE). Participants are still being monitored, but as is common in trials, an interim analysis was done. The median follow up time at this analysis was it over a 56.6 months. The median time to relapse was 44.2 months (vaccine) versus 30.6 (placebo), which was statistically significant (p = 0.045). The overall survival has not yet been reached with over 95% of the vaccine and 91% of the placebo arms alive at this follow-up. No serious side effects were attributed to the vaccine and the side effects were similar in both groups.
Although similar types of vaccines have been tested previously, this is the first trial to show a statistically significant improvement in progression-free survival in follicular lymphoma patients treated with the vaccine. Previous trials included patients who had partial or complete responses, whereas this trial only vaccinated patients who had no detectable tumor remaining after chemotherapy. Under these conditions, the investigators hypothesized that the vaccine could hold minimal residual disease in check. It is also important to point out that the trial had originally enrolled 234 participants, but 25% did not achieve the 6 month remission. Those patients require further therapy options.
The study is exciting for the field of vaccines, but some new questions arise, including: how does the now standard Rituxan fit into this regimen and is there a better time point to give a vaccine (pre-chemo, in conjunction with chemo).
